



**GlaxoSmithKline**  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709  
Tel. 919 483 2100  
www.gsk.com

April 2013

**Subject: PEDIARIX® [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine] Supply Update**

Dear Healthcare Provider:

On behalf of GlaxoSmithKline (GSK) Vaccines, I would like to take this opportunity to make you aware of the steps GSK is taking with regard to supply for its combination diphtheria, tetanus, and acellular pertussis (DTaP) vaccine, PEDIARIX, in light of ongoing market supply constraints on combination DTaP vaccines.

In response to the shortage of combination DTaP vaccine from another supplier to the marketplace beginning in April 2012, GSK took steps to meet increased demand for its combination DTaP vaccine by increasing production.

Having recently become aware that the current marketplace shortage is now expected to continue into the summer of 2013, GSK will continue its efforts to increase production of PEDIARIX to help meet market demand. However, due to the long lead time required to manufacture vaccines, the additional supply of PEDIARIX is not anticipated to be available until Q3 2013.

Unfortunately, due to the continued shortage of combination DTaP vaccine, GSK now expects to be able to cover only a portion of the continued shortage with PEDIARIX. To help ensure that some quantity of combination DTaP vaccine remains available to as many providers as possible, GSK will institute allocations of PEDIARIX until September 2013 with the intention of removing these allocations once DTaP combination vaccine availability increases.

Please be aware that GSK currently expects to have sufficient supply of INFANRIX® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) to cover the potential shortage of PEDIARIX that may result from our allocation efforts.

GSK shares your goal of vaccinating all appropriate infants against diphtheria, tetanus, and pertussis. I want to extend my sincerest apologies for any frustration or disruption to your practices and facilities this short-term allocation of PEDIARIX may cause.

Please do not hesitate to contact GlaxoSmithKline with any further questions or concerns. You may reach out to us at 1.866.GSK.VACC (1.866.475.8222) or contact your GlaxoSmithKline Vaccines Representative today.

Sincerely,

A handwritten signature in black ink that reads "Mike Thomas".

Michael F. Thomas  
US Vaccines Business Unit Head